Don't see a perfect job? Apply opportunistically. at Abata Therapeutics

Boston, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalIndustries

Requirements

Not specified

Responsibilities

Not specified

Skills

Key technologies and capabilities for this role

ChemoproteomicsSmall Molecule Drug DiscoveryDrug DevelopmentBiotechnologyPharmacology

Questions & Answers

Common questions about this position

What is the salary for this position?

This information is not specified in the job description.

Is this role remote or onsite?

The position is onsite in Boston, MA.

What skills are required for this opportunity?

This information is not specified in the job description.

What is the company culture like at Jnana Therapeutics?

Jnana features a diverse, passionate team dedicated to advancing therapies for challenging diseases, with a collaborative, purpose-driven culture that fosters innovation, urgency, and belonging.

How should I apply if there's no perfect job match?

Apply opportunistically through the provided link even if no specific job is posted, as Jnana is open to considering candidates whose skills and experience might be a fit.

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free